Silence Therapeutics receives two patents for RNA interference therapeutics

8 September 2010, 1:52 am

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).... Read More »

More Topics from "Articles"

• EVTN Files Patents for Oil Spill Recovery Technology
• Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
• Utah patents for doors, syringes and radar
• Court rejects rivals' motion to void patents on Teva's Copaxone
• RIM Wants Billboards That Know How Fast You're Driving [Patents]
• RIM Patents Adaptive Roadside and Pedestrian Billboard Systems
• Trident Microsystems Announces Plans to License Foundational MEMC Patents
• Solar Patents at record in 2009-Shine on Solar edition of CEPGI
• New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies